The deal is sealed. This week contracts were signed to make it official: ISA will move to the new BioPartner 5 building as soon as it is ready.
Over the past period we have been expanding and further growth is anticipated. We’re on a roll and rapidly outgrowing our current offices and lab space. Our collaboration with Regeneron for our lead asset ISA101b is booming and we are about to enter the clinic with other therapeutics in our pipeline.
To accommodate future expansion – in line with an aggressive growth strategy – we will move to a new building and double in
Leiden, The Netherlands, 01 July 2020 — ISA Pharmaceuticals B.V., today announced that it received Orphan Drug Designation from the Food and Drug Administration (FDA) in the USA for its lead product ISA101b for treatment of Human Papilloma Virus type 16 (HPV16)-positive cervical cancer.
According to the latest statistics of the Centers for Disease Control and Prevention, HPV causes more than 34,000 cases of cancer in the United States each year. Cervical cancer is the most common HPV-associated cancer in women, with HPV16 being responsible for approximately 50% of cases. HPV16-positive cervical cancer is the number 2 cause of cancer for women in